Trial Information

Summary: An Open-Label Pilot Study of Namenda (memantine hydrochloride) in Adult Subjects with Attention Deficit Hyperactivity Disorder (ADHD)

The main aim of this research study is to assess the effectiveness and tolerability of an investigational medication in Adults with Attention Deficit Hyperactivity Disorder (ADHD) and Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS). ADHD NOS is a label used to describe adults who have symptoms of ADHD that can appear in late childhood, or even adulthood. This study is a 12-week open-label (involves active medication only, no chance of placebo) trial of Namenda. Namenda is FDA approved for the treatment of Alzheimer’s disease, but is not approved for treatment of ADHD. Study participation could last for up to 14 weeks from the initial psychiatric evaluation. Participants will receive an evaluation and study visits at no cost.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.